Memorial Hospital Research Laboratories

The Charles Rudin Lab

Charles M. Rudin, MD, PhD

Physician-scientist Charles M. Rudin, Chief of the Thoracic Oncology Service, leads research that focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models including patient-derived xenografts. These studies are integrated with early phase clinical trials.

Featured News

Atypical Small Cell Carcinoma, a Rare Type Lung Cancer, Identified by MSK Research Team

A team of doctors and researchers at MSK have identified a new, rare type of small cell lung cancer that primarily affects younger people who have never smoked. Learn how one 19-year-old patient sparked a detective story.

In the Lab

Cyclotron engineer and nuclear pharmacist

New Imaging Detects Deadly Lung and Prostate Cancers, May Improve Treatment

Learn how a new imaging technique could improve detection and treatment of certain aggressive lung and prostate cancers.

Scientists Learn More about How Lung Cancer Becomes Resistant to Drugs

By switching from one cellular identity to another, lung cancer cells can evade targeted therapies. MSK scientists are trying to stop that from happening.

View All Featured News

Publications Highlights

Rekhtman et al., Chromothripsis-mediated small cell lung carcinoma. Cancer Discov 2024 (DOI: 10.1158/2159-8290.CD-24-0286).

Redin et al., SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing. J Hematol Oncol 2024 (DOI: 10.1186/s13045-024-01572-3).

Quintanal-Villalonga et al., CDC7 inhibition impairs neuroendocrine transformation in lung and prostate tumors through MYC degradation. Signal Transduct Target Ther 2024 (DOI: 10.1038/s41392-024-01908-y).

Rudin et al., Clinical benefit from immunotherapy in patients with SCLC is associated with tumor capacity for antigen presentation. J Thorac Oncol 2023 (DOI: 10.1016/j.jtho.2023.05.008).

Quintanal-Villalonga A, Durani V, Sabet A, Redin E, Kawasaki K, Shafer M, Karthaus WR, Zaidi S, et al. Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers. Sci Transl Med. (2023)

View All Publications

People

Charles M. Rudin, MD, PhD

Physician-scientist Charles Rudin focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models.
MD, PhD, University of Chicago Pritzker School of Medicine

[email protected]: Email Address
View physician profile: Physician profile

Members

Álvaro Quintanal Villalonga
Director, Translational Medicine-Oncology in AstraZeneca

Barbara Mello, PhD — Barbara De Mello
Senior Research Assistant

Laura Eibler

Graduate Student

Jorge Nuñez

Graduate Student

Esther Redin Resano
Assistant Member and Lab Co-Director

Lab Alumni

Viola Allaj
Research Associate, Pfizer Inc.

Metamia Ciampricotti
Medical Science Liaison, Tempus AI

John Poirier — John T. Poirier
Assistant Professor, Director, Preclinical Therapeutics Program, Perlmutter Cancer Center, NYU Langone Health

Eric Gardner
Postdoctoral Research Fellow, Harold Varmus Lab, WCMC

Christopher Hulton, BS, MS — Christopher Hulton
Senior Scientist, Drug Discovery Biology, Treeline Biosciences, Cambridge, MA

Corrin Wohlhieter
Senior Associate, Clarion Life Sciences

James Laird
Medical Resident, Yale School of Medicine

Pictured: Benjamin Lok — Benjamin Lok
Clinician-Scientist, Princess Margaret Cancer Centre and Assistant Professor of Radiation Oncology, University of Toronto

Nisarg Shah
Lab Manager, University of Pennsylvania

Andrew Chow
Clinical Director in Oncology Early Development, Merck

Emily Costa
Postdoctoral Fellow, Rockefeller University

W. Victoria Lai — Victoria Lai
Senior Global Development, Late Oncology Lung, Astra Zeneca

Hirokazu Taniguchi
Assistant professor, Nagasaki University Hospital, Department of Respiratory Medicine

Rebecca Caeser
Senior Scientist, National Cancer Center, Singapore

Arielle Elkrief
Assistant Professor & Clinician Scientist, University of Montreal; Co-Director CHUM Microbiome Centre

Jaspers Janneke — Janneke Jaspers
Technology Transfer Officer, Starfish Innovations

Kenta Kawasaki
Assistant Professor, Keio University, Japan

Linde Miles
Assistant Professor, University of Cincinnati

Evelyn Nguyen
Consultant, Boston Consulting Group

Harsha Sridhar
Graduate Student, Francis Crick Institute

Kathryn M. Tully
Scientist 1 at Ratio Therapeutics

Lab Affiliations

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Career Opportunities

Apply now

Get in Touch

[email protected]

Lab Head Email

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Charles M. Rudin discloses the following relationships and financial interests:

AbbVie
Professional Services and Activities
Amgen
Professional Services and Activities
Boehringer Ingelheim
Professional Services and Activities
D2G Oncology
Professional Services and Activities
Daiichi Sankyo
Intellectual Property Rights
Earli Inc.
Equity

Harpoon Therapeutics, Inc.
Professional Services and Activities
Jazz Pharmaceuticals
Professional Services and Activities
Mariana Oncology, Inc.
Professional Services and Activities
Scorpion Therapeutics, Inc.
Professional Services and Activities
Treeline Biosciences, Inc.
Professional Services and Activities

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures